TLPH Stock Summary and Trading Ideas (Talphera | NASDAQ:TLPH)

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Talphera trades on the NASDAQ stock market under the symbol TLPH.

As of April 10, 2026, TLPH stock price climbed to $0.82 with 14,387 million shares trading.

TLPH has a beta of 0.50, meaning it tends to be less sensitive to market movements. TLPH has a correlation of 0.01 to the broad based SPY ETF.

TLPH has a market cap of $41.04 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that TLPH belongs to (by Net Assets): VXF.

TLPH has outperformed the market in the last year with a price return of +65.7% while the SPY ETF gained +25.4%. However, in the short term, TLPH had mixed performance relative to the market. It has underperformed in the last 3 months, returning -22.6% vs -1.7% return in SPY. But in the last 2 weeks, TLPH shares have fared better than the market returning +6.1% compared to SPY +5.5%.

TLPH support price is $.76 and resistance is $.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TLPH shares will trade within this expected range on the day.